Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study

Poor outcomes have been reported in patients with type 2 diabetes and coronavirus disease 2019 (COVID-19); thus, it is mandatory to explore novel therapeutic approaches for this population. In a multicenter, case-control, retrospective, observational study, sitagliptin, an oral and highly selective...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes care 2020-12, Vol.43 (12), p.2999-3006
Hauptverfasser:	Solerte, Sebastiano Bruno, D'Addio, Francesca, Trevisan, Roberto, Lovati, Elisabetta, Rossi, Antonio, Pastore, Ida, Dell'Acqua, Marco, Ippolito, Elio, Scaranna, Cristiana, Bellante, Rosalia, Galliani, Silvia, Dodesini, Alessandro Roberto, Lepore, Giuseppe, Geni, Francesca, Fiorina, Roberta Maria, Catena, Emanuele, Corsico, Angelo, Colombo, Riccardo, Mirani, Marco, De Riva, Carlo, Oleandri, Salvatore Endrio, Abdi, Reza, Bonventre, Joseph V, Rusconi, Stefano, Folli, Franco, Di Sabatino, Antonio, Zuccotti, Gianvincenzo, Galli, Massimo, Fiorina, Paolo
Format:	Artikel
Sprache:	eng
Schlagworte:	Betacoronavirus Clinical outcomes Coronavirus Coronavirus Infections Coronaviruses COVID-19 Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - drug therapy Emerging Therapies: Drugs and Regimens Health services Hospitalization Humans Insulin Italy Mortality Observational studies Oxygen Oxygen content Pandemics Patients Peptidase Peptidases Pneumonia, Viral Research design Retrospective Studies SARS-CoV-2 Sitagliptin Phosphate - therapeutic use Viral diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!